CLEVELAND, United Kingdom—Cambridge Research Biochemicals (CRB) has announced the signing of a non-exclusive license with LI-COR Biosciences for the development, manufacturing and sale of IRDye and IRDye QC-1 near-infrared dye-labeled peptides for research use only. The partnership is one of many license agreements CRB has enacted in order to provide the largest possible selection of dyes for peptide labeling, with other partners including Life Technologies, GE-Healthcare, Atto-Tec, Cyanagen and Biosearch Technologies. Financial details were not disclosed.

 

“We are very excited that Cambridge Research Biochemicals now offers our IRDye near-infrared dye technologies. The expertise and quality for custom peptide synthesis from CRB, coupled with LI-COR dye technologies, will enable our customers to create innovative solutions for their research needs,” Bambi Reynolds, licensing and intellectual property manager of biotechnology at Li-COR, said in a press release.